Genomic analysis in active surveillance

For patients newly diagnosed with prostate cancer, the most significant question is whether the ‘truly malignant’ disease has been identified. This review will provide an overview of current prostate cancer genomic and biomarker discovery – validation strategies geared towards identifying aggressive, clinically significant disease at the time of diagnosis.